این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Blood and Cancer، جلد ۸، شماره ۳، صفحات ۷۲-۷۴
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran
چکیده انگلیسی مقاله Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the patients' response and also their preference could be a reliable method for assessing the efficacy of bypassing agents; therefore, we designed a multi-centric discrete choice experiment study to assess the factors that affect the efficacy of bypassing agents. Methods: Hemophilic patients older than 2 years with inhibitors who required bypassing agents for the treatment of bleeding episodes were eligible to participate in the study. Patients' preference toward treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design on a phone interview. Results: 80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was18.6 years (range, 2-50 years). 47 patients (58%) preferred to receive FEIBA, 21 patients (21.2%) favored Aryoseven and 12 (14.8%) patients claimed no difference between the two products. Conclusion: Our results indicated that according to the DCE method, patients preferred Feiba to Aryoseven while the main reason was their higher efficacy. In addition, adverse reactions in both groups were almost equal. As a result, it seems that presence of both products in the market for hemophilic patients with inhibitors is absolutely essential.
کلیدواژه‌های انگلیسی مقاله Hemophilic patients, Patients’ response, Bypassing agents
نویسندگان مقاله بهناز حبیب پناه | behnaz habibpanah
pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

زهرا تارا | zahra tara
pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

فاطمه ملک | fatemeh malek
pediatric congenital hematologic disorders research center, mofid children’s hospital, shahid beheshti university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

رضوان اردشیری | rezvan ardeshiri
shahid dastgheib hemophilia center. shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

تهمینه سلیمی | tahmineh salimi
comprehensive hemophilia care center, iran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (Iran university of medical sciences)

بلقیس فصیح | belgheis fasih
aliasghar hospital, zahedan university of medical sciences, zahedan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی زاهدان (Zahedan university of medical sciences)

محمدرضا محمد رضا | mohammad reza managhchi
thrombosis hemostasis research center, imam khomeini hospital, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

اعظم صافی | azam saafi


نشانی اینترنتی http://www.ijbc.ir/browse.php?a_code=A-10-1-132&slc_lang=fa&sid=en
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده 0|
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات